# Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

> **NCT03905135** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 8 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma NOS
- Mycosis Fungoides
- Sezary Syndrome
- Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** rhIL-15
- **DRUG:** rhIL-15
- **BIOLOGICAL:** Avelumab

## Key facts

- **NCT ID:** NCT03905135
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-07
- **Primary completion:** 2021-03-25
- **Final completion:** 2022-05-17
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03905135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03905135, "Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03905135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*